You are here
Clinical Study To Proceed With Oral Formulation of Telintra in Patients With Myelodysplastic Syndrome
TELINTRA is a novel small molecule that has been shown in preclinical testing to have myelorestorative activity when administered orally or by infusion. It was discovered using Telik's proprietary TRAP(TM) small molecule drug discovery technology.
The myelodysplastic syndromes are a group of bone marrow disorders characterized by the abnormal formation, development and maturation of blood elements. In some cases, MDS progresses to acute leukemia. There are an estimated 10,000 to 15,000 new cases of MDS diagnosed annually in the U.S., according to the American Cancer Society.
Source: Telik, Inc.